These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 26041296

  • 41. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
    de la Torre JC.
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
    [Abstract] [Full Text] [Related]

  • 42. The glycoprotein precursor gene of Junin virus determines the virulence of the Romero strain and the attenuation of the Candid #1 strain in a representative animal model of Argentine hemorrhagic fever.
    Seregin AV, Yun NE, Miller M, Aronson J, Smith JK, Walker AG, Smith JN, Huang C, Manning JT, de la Torre JC, Paessler S.
    J Virol; 2015 Jun; 89(11):5949-56. PubMed ID: 25810546
    [Abstract] [Full Text] [Related]

  • 43. Identification of a broad-spectrum arenavirus entry inhibitor.
    Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM.
    J Virol; 2008 Nov; 82(21):10768-75. PubMed ID: 18715909
    [Abstract] [Full Text] [Related]

  • 44. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.
    Radoshitzky SR, Kuhn JH, de Kok-Mercado F, Jahrling PB, Bavari S.
    Expert Opin Drug Discov; 2012 Jul; 7(7):613-32. PubMed ID: 22607481
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.
    Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB.
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1342. PubMed ID: 22022624
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Retrovirus-Based Surrogate Systems for BSL-2 High-Throughput Screening of Antivirals Targeting BSL-3/4 Hemorrhagic Fever-Causing Viruses.
    Radoshitzky SR, Soloveva V, Gharaibeh D, Kuhn JH, Bavari S.
    Methods Mol Biol; 2018 Oct; 1604():393-403. PubMed ID: 28986850
    [Abstract] [Full Text] [Related]

  • 54. Determining the Virus Life-Cycle Stage Blocked by an Antiviral.
    Sepúlveda CS, García CC, Damonte EB.
    Methods Mol Biol; 2018 Oct; 1604():371-392. PubMed ID: 28986849
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases.
    Afowowe TO, Sakurai Y, Urata S, Zadeh VR, Yasuda J.
    Viruses; 2022 Dec 30; 15(1):. PubMed ID: 36680145
    [Abstract] [Full Text] [Related]

  • 60. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.
    Neuman BW, Bederka LH, Stein DA, Ting JP, Moulton HM, Buchmeier MJ.
    Antimicrob Agents Chemother; 2011 Oct 30; 55(10):4631-8. PubMed ID: 21825302
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.